Table 2.
Quality of life patient-reported outcomes at baseline, day 28, day 100, and day 180 post transplant.
| Assessment | All (N = 87) | Tocilizumab cohort (N = 25) | Control cohort (N = 62) | ||||
|---|---|---|---|---|---|---|---|
| No. of participants | Assessment data, mean score (SD) | No. of participants | Assessment data, mean score (SD) | No. of participants | Assessment data, mean score (SD) | P value | |
| Depression | |||||||
| Baseline | 85 | 35.7 (10.9) | 25 | 34.8 (8.8) | 60 | 36.1 (11.7) | 0.95 |
| Day 28 | 79 | 39.5 (11.7) | 22 | 42.7 (10.2) | 57 | 38.2 (12.1) | 0.03 |
| Day 100 | 74 | 37.9 (12.0) | 20 | 39.5 (9.1) | 54 | 37.3 (12.9) | 0.16 |
| Day 180 | 57 | 37.1 (11.4) | 12 | 38.6 (9.9) | 45 | 36.7 (11.8) | 0.40 |
| Anxiety | |||||||
| Baseline | 85 | 15.4 (4.4) | 25 | 15.9 (5.0) | 60 | 15.2 (4.2) | 0.66 |
| Day 28 | 79 | 16.7 (4.2) | 22 | 17.8 (4.4) | 57 | 16.3 (4.1) | 0.10 |
| Day 100 | 73 | 16.6 (4.6) | 19 | 19.2 (6.0) | 54 | 15.6 (3.7) | 0.02 |
| Day 180 | 57 | 16.6 (5.1) | 12 | 18.2 (6.6) | 45 | 16.2 (4.6) | 0.44 |
| Fatigue, intensity | |||||||
| Baseline | 85 | 3.4 (2.1) | 25 | 2.5 (1.5) | 60 | 3.9 (2.2) | 0.003 |
| Day 28 | 79 | 4.0 (1.8) | 22 | 4.2 (1.7) | 57 | 3.9 (1.9) | 0.36 |
| Day 100 | 73 | 3.4 (2.0) | 18 | 3.7 (2.0) | 55 | 3.3 (2.0) | 0.52 |
| Day 180 | 55 | 3.7 (1.8) | 12 | 4.2 (1.1) | 43 | 3.6 (2.0) | 0.36 |
| Fatigue, duration | |||||||
| Baseline | 85 | 6.5 (4.5) | 25 | 5.4 (4.1) | 60 | 7.0 (4.6) | 0.17 |
| Day 28 | 79 | 8.8 (4.5) | 22 | 9.6 (4.7) | 57 | 8.5 (4.4) | 0.28 |
| Day 100 | 74 | 8.0 (4.5) | 19 | 8.9 (4.4) | 55 | 7.7 (4.6) | 0.31 |
| Day 180 | 55 | 8.3 (4.5) | 12 | 9.2 (4.0) | 43 | 8.1 (4.6) | 0.61 |
| Fatigue, interference | |||||||
| Baseline | 85 | 2.2 (2.3) | 25 | 1.5 (1.8) | 60 | 2.5 (2.4) | 0.09 |
| Day 28 | 79 | 2.9 (2.4) | 22 | 2.8 (1.9) | 57 | 2.9 (2.5) | 0.79 |
| Day 100 | 74 | 2.4 (2.3) | 19 | 2.3 (1.8) | 55 | 2.5 (2.5) | 0.83 |
| Day 180 | 55 | 2.3 (2.1) | 12 | 1.9 (1.7) | 43 | 2.5 (2.2) | 0.53 |
| Pain, intensity | |||||||
| Baseline | 84 | 1.5 (2.0) | 25 | 1.5 (1.7) | 59 | 1.5 (2.2) | 0.50 |
| Day 28 | 79 | 1.9 (1.9) | 22 | 3.0 (1.8) | 57 | 1.5 (1.8) | <.001 |
| Day 100 | 73 | 1.5 (1.6) | 18 | 1.8 (1.8) | 55 | 1.5 (1.6) | 0.61 |
| Day 180 | 57 | 2.0 (2.0) | 12 | 2.2 (2.6) | 45 | 1.9 (1.9) | 0.93 |
| Pain, interference | |||||||
| Baseline | 84 | 1.3 (2.0) | 25 | 0.9 (1.7) | 59 | 1.4 (2.1) | 0.22 |
| Day 28 | 78 | 1.6 (2.2) | 22 | 2.0 (2.0) | 56 | 1.5 (2.4) | 0.08 |
| Day 100 | 73 | 1.6 (2.3) | 18 | 1.6 (1.8) | 55 | 1.6 (2.4) | 0.64 |
| Day 180 | 57 | 2.0 (2.4) | 12 | 1.6 (2.4) | 45 | 2.1 (2.4) | 0.42 |
| Sleep | |||||||
| Baseline | 85 | 7.0 (4.3) | 25 | 7.4 (4.1) | 60 | 6.8 (4.5) | 0.44 |
| Day 28 | 79 | 7.3 (4.5) | 22 | 8.4 (4.4) | 57 | 6.9 (4.5) | 0.12 |
| Day 100 | 75 | 6.8 (4.3) | 20 | 7.9 (4.5) | 55 | 6.3 (4.3) | 0.16 |
| Day 180 | 57 | 6.9 (3.9) | 12 | 8.5 (4.0) | 45 | 6.5 (3.8) | 0.13 |